Search results
Results from the WOW.Com Content Network
About 45 out of 100,000 people develop infectious mono each year in the United States. [5] Nearly 95% of people have had an EBV infection by the time they are adults. [5] The disease occurs equally at all times of the year. [9] Mononucleosis was first described in the 1920s and is colloquially known as "the kissing disease". [14]
There are several forms of Epstein–Barr virus (EBV) infection. These include asymptomatic infections, the primary infection, infectious mononucleosis, and the progression of asymptomatic or primary infections to: 1) any one of various Epstein–Barr virus-associated lymphoproliferative diseases such as chronic active EBV infection, EBV+ hemophagocytic lymphohistiocytosis, Burkitt's lymphoma ...
Epstein–Barr virus infectious mononucleosis (Mono) Diagnostic modalities for infectious mononucleosis include: Person's age, with highest risk at 10 to 30 years. Medical history, such as close contact with other people with infectious mononucleosis; Physical examination, including palpation of any enlarged lymph nodes in the neck, or enlarged ...
Yes, you can get norovirus twice. “People can get infected with norovirus countless times,” says infectious disease expert Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center ...
Epstein–Barr virus–associated lymphoproliferative diseases (also abbreviated EBV-associated lymphoproliferative diseases or EBV+ LPD) are a group of disorders in which one or more types of lymphoid cells (a type of white blood cell), i.e. B cells, T cells, NK cells, and histiocytic-dendritic cells, are infected with the Epstein–Barr virus (EBV).
Chronic active EBV infection or in its expanded form, chronic active Epstein–Barr virus infection is a very rare and often fatal complication of Epstein–Barr virus (EBV) infection that most often occurs in children or adolescents of Asian or South American lineage, although cases in Hispanics, Europeans and Africans have been reported. [1]
They are also expensive, risk causing resistance to antiviral agents, and (in 1% to 10% of cases) can cause unpleasant side effects. [1] Several clinical trials for a vaccine were conducted in 2006–2008. [4] [5] [6] The viral proteins Gp350/220 are a primary target, [7] but this would only block infection of B cells, not epithelial cells.
For premium support please call: 800-290-4726 more ways to reach us